Kenkare-Mitra Sara 4/A

What Happened
Sara Kenkare‑Mitra, a director of Unicycive Therapeutics, received two restricted stock unit (RSU) awards on May 14, 2026: 84,200 RSUs and 42,100 RSUs. Both grants are reported as derivative acquisitions at a $0.00 per‑share price (typical for equity compensation). Total RSUs granted = 126,300. This is an award/compensation event (code A), not an open‑market purchase or sale.

Key Details

• Transaction date: May 14, 2026 (reported on an amended Form 4 filed June 15, 2026). The amendment suggests the filing was made after the original transaction date.
• Price: $0.00 per share (RSU grant).
• Grant breakdown and vesting (per footnotes):
  • 84,200 RSUs (F1): 11,694 shares vest upon grant; 2,339 shares vest monthly over 31 months beginning June 1, 2026, subject to continued service.
  • 42,100 RSUs (F2): 17,542 shares vest upon grant; 3,508 shares vest monthly over 7 months beginning June 1, 2026, subject to continued service.
• Shares owned after transaction: Not disclosed in the supplied filing details.
• No 10b5‑1 plan, tax‑withholding sale, or immediate cashless disposition is indicated in the provided information.
• Filing status: This is an amended Form 4 filed about one month after the grant date, which may reflect a late or corrected reporting.

Context
RSUs are a form of equity compensation that convert into common stock when they vest; the $0 grant price means these were awards, not purchases. Portions of these grants vest immediately (per the footnotes) while the remainder vests monthly subject to continued service — they do not necessarily signal a buy or sell decision by the director. As with typical compensation grants, these are primarily a retention/incentive mechanism rather than a direct market sentiment indicator.